Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / ERBB2



This biomarker is also known as:
  • Receptor tyrosine-protein kinase erbB-2,
  • Metastatic lymph node gene 19 protein,
  • MLN19,
  • MLN 19,
  • HER-2,
  • CD_antigen=CD340,
  • HER2,
  • CD340,
  • Proto-oncogene c-ErbB-2,
  • HER-2/neu,
  • v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian),
  • TKR1,
  • NGL,
  • Tyrosine kinase-type cell surface receptor HER2,
  • NEU,
  • p185erbB2,
  • Proto-oncogene Neu,
  • v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog),
  • c-ErbB-2,

View in BioMuta


ERBB2, often known as HER-2/neu, a single-pass type I membrane protein, is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. It is part of several cell surface receptor complexes. ERBB2 has no ligand binding domain of its own, and needs a coreceptor for ligand binding. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele Ile654/Ile655. There are several transcript variants resulting from alternative splicing events. Some isoforms have not been fully characterized yet.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


Performance Comment



Phase: Two
QA State: Under Review


Amplification and/or overexpression of the ERBB2 gene has been reported in numerous cancers, including breast and ovarian tumors. Studies have suggested that ERBB2 overexpression represented a major negative prognostic indicator for patients with several human cancers, including endometrial carcinomas

Performance Comment

Despite many promising new markers for ovarian cancer, CA125 remains the single best biomarker in the phase II and phase III specimens tested in this study.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.
Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.